| Objective: Through anti-parainfluenza virus in vitro,screen of effectivechinese proprietary, named BingyanqingⅣ; Apply BingyanqingⅣto treatTanrexing bronchitis because of human parainfluenza virus, Observe clinicalefficacy, providing an effective traditional chinese prescription for thetreatment of the type of Tanre bronchitis because of human parainfluenza virus.Methods:①Experiment Study Take the Hep-2 cell as the viral host, forthe toxicity of the BingyanqingⅣand Ribavirin. Draw the 50% toxicconcentration (CC50); Observe the toxicity of Hep-2 cells of the BingyanqingⅣBingyanqingⅣ,. draw half of the toxic drug concentrations (TCID50);Doingthe BingyanqingⅣand Ribavirin impaction on the cytopathic, calculation50% effective concentration, and measure Therapeutic Index (TI=CC50/EC50).②Clinical Study Collect suspected cases of parainfluenza virusinfection,which have the epidemiological history and clinical symptoms,all of them comes from Emergency Department and Respiratory Outpatients:According Enzyme-linked immunosorbent assay (ELISA), doing the detection.of antibody, Confirmed experimental cases who meet the entry criteria, A totalof 54 cases, the differences of two groups in terms of gender, age, severitylevel are not significant, statistical comparability (P＞0.05). 54 patientsare randomly assigned to the BingyanqingⅣgroup (30 cases) and control groupribavirin(24 cases), The observation will continue for 9 days.Summary:①According to the vitro, we can conclude that the TI ofBingyanqingⅣand Ribavirin are 4.27, 25.59, that to say, all the two groupshave inhibition to cytopathic, but BingyanqingⅣgroup is not as good asRibavirin ffroupe, the latter is superior to the former, in security respects. ②According Clinical study, We can draw that comparing Integral condition,therapy group and control group, in the aspects of cough,expectoration,fever,rale and lymphocyte count, have notable efficacy (P＜0.05); and therapygroup is superior to control group, and also have statistical significance(P＜0.05). About the onset time of the main symptoms, The former is slowerthan the contral groupe, did not have statistical significance(P＞0.05); Inthe total clinica efficacy, Therapy group is 70.00% and control group is66.66%, there have not any statistical significance(P＞0.05)either; ButBingyanqingⅣhave the advantage trend than the Ribavirin group.Conclusion: Integrated recognizing,treatment level, research progressInformation about parainfluenza virus, according the experiments in vitroand clinic, we can conclude that: 1. Experiment Study: BingyanqingⅣcananti parainfluenza virus, but is not as good as Ribavirin. 2. Clinical Study:BingyanqingⅣcan improve clinical symptoms, the onset time of the mainsymptoms and the total clinica efficacy have no statistical significancecompared with Ribavirin. 3. It is suggested from this study, the efficacyof BingyanqingⅣtreate the type of Tanre bronchitis because of humanparainfluenza virus need continuing study.
|
PDF Full Text Request